文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

重症新型冠状病毒肺炎患者的血浆置换:单中心经验

Plasma Exchange in Patients With Severe Coronavirus Disease 2019: A Single-Center Experience.
PubMed 文献 · Crit Care Explor · 2021-08-20
一句话结论回顾性病例对照研究提示,对重症COVID-19伴高炎症综合征特征患者行血浆置换可改善30天生存(67.9% vs 42.9%),但需RCT证实。

血浆置换中位3次/人,每次置换50 mL/kg或最大4 L,未发生相关并发症。血浆置换后炎症标志物、终末器官损伤及内皮活化指标显著下降,体温正常化、肺功能改善、血管升压药需求减少,且末次置换后仍维持;对照组无此变化。30天生存率血浆置换组优于对照组(67.9% vs 42.9%,p=0.044),多变量分析死亡HR 0.27(95%CI 0.11–0.68,p=0.005)。

要点

  • 重症COVID-19伴高炎症综合征临床/实验室证据者,血浆置换后30天生存67.9% vs 标准治疗42.9%(p=0.044)。
  • 多变量分析血浆置换 vs 标准治疗死亡HR 0.27(95%CI 0.11–0.68,p=0.005),提示生存获益。
  • 血浆置换方案:每次50 mL/kg体重或最大4 L,中位3次/人,治疗期间无相关并发症。
  • 血浆置换后炎症与内皮活化标志物、终末器官损伤指标显著下降,体温正常化、肺功能改善、升压药需求减少,末次置换后维持。
  • 对照组基线临床与实验室参数可比,但未观察到上述改善;结论需RCT确认。

适用人群与场景

  • 血浆置换组与标准治疗组按年龄、性别、疾病严重程度及高炎症综合征特征匹配。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 血浆置换:每次置换血浆量50 mL/kg体重或最大4 L,中位每例患者3次血浆置换。
  • 原文未提及其他药物剂量、给药途径、频次或目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:单中心回顾性病例对照研究;样本量28例接受血浆置换的重症COVID-19患者,与匹配的标准治疗对照比较。
  • 干预:血浆置换(50 mL/kg或最大4 L,中位3次/人)vs 标准治疗;主要终点为死亡率及临床和实验室参数变化。
  • 30天生存率:血浆置换组67.9% vs 对照组42.9%(p=0.044);多变量分析死亡HR 0.27(95%CI 0.11–0.68,p=0.005)。
  • 血浆置换后炎症与生化标志物、终末器官损伤及内皮活化指标显著降低,体温正常化、肺功能改善、升压药需求减少,末次置换后维持;对照组无此变化。
  • 血浆置换期间无相关并发症。

证据类型、等级与局限

  • 证据类型:单中心回顾性病例对照研究。
  • 局限:回顾性设计、单中心、样本量小(28例血浆置换患者),原文指出需随机对照试验确认。

对床旁实践的改变

  • 对重症COVID-19伴高炎症综合征特征患者,可考虑血浆置换(50 mL/kg或最大4 L,中位3次)作为潜在治疗策略,但证据来自回顾性研究,需RCT证实。
  • 原文未提及适用与不适用人群的具体排除标准,临床决策需结合个体情况。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Recent evidence suggests a multilevel inflammatory syndrome as a driving factor in some of the most severely ill coronavirus disease 2019 patients with overlapping features to other hyperinflammatory or autoimmune diseases. Therefore, plasma exchange is considered as potential therapy in these patients.

OBJECTIVES: We characterize the longitudinal therapeutic efficacy and safety profile of plasma exchange in critically ill patients with clinical and laboratory evidences of coronavirus disease 2019-related immunopathology.

DESIGN SETTING AND PARTICIPANTS: A retropsective case-control study of critically ill coronavirus disease 2019 patients treated with plasma exchange at Heidelberg University Hospital between March and December 2020. Plasma exchange-treated patients were compared with coronavirus disease 2019 patients on standard therapy matched for age, gender, disease severity, and features of hyperinflammatory syndrome.

MAIN OUTCOME AND MEASURES: Mortality rate and course of clinical and laboratory parameters in response to plasma exchange were assessed in coronavirus disease 2019 patients and in patients on standard care. A plasma volume of 50 mL per kg body weight or a maximum of 4 L was exchanged.

RESULTS: In total, 28 critically ill coronavirus disease 2019 patients were treated with a median of three plasma exchange procedures per patient. No relevant complications occurred during plasma exchange therapy. Inflammatory and biochemical markers of end-organ damage and endothelial activation were significantly reduced following plasma exchange together with normalization of body temperature, improved pulmonary function, and reduced vasopressor demand. Most importantly, these improvements were maintained after the last plasma exchange. In contrast, no such effects were observed in the control group, although baseline clinical and laboratory parameters were comparable. Kaplan-Meier analysis showed improved 30-day survival in the plasma exchange group compared with the control group (67.9% vs 42.9%; p = 0.044). In a multivariable analysis, the hazard ratio for death was 0.27 (95% CI, 0.11-0.68; p = 0.005) with plasma exchange versus standard care.

CONCLUSIONS AND RELEVANCE: Our data provide further evidence for plasma exchange as a novel therapeutic strategy in a subset of critically ill coronavirus disease 2019 patients by potentially reversing the complex coronavirus disease 2019 immunopathology. Randomized controlled trials are underway to confirm these positive results.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Nusshag C, Morath C, Speer C, et al. Plasma Exchange in Patients With Severe Coronavirus Disease 2019: A Single-Center Experience. Crit Care Explor. 2021. PMID: 34476404. doi:10.1097/CCE.0000000000000517

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。